Results 81 to 90 of about 28,272 (264)
The FEBS Journal, EarlyView.High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz +9 more
wiley +1 more source
Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Statin‐mediated efficacy of lowering low‐density lipoprotein (LDL) cholesterol varies in each individual, and its diminished response is associated with worse outcomes.
Naoto Kuyama +11 more
doaj +1 more source
A PCSK9 e sua relevância clínica com os novos alvos terapêuticos contra a dislipidemia [PDF]
, 2012 This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its ...
Ferreira, Carlos Eduardo dos Santos +2 more
core +1 more source
Experimental Physiology, EarlyView.Abstract Current literature on the metabolic effects of long‐distance hiking is limited to case studies with discrepant findings, and no prior studies have examined the role of diet in shaping these outcomes. In this study, we investigated changes in lipid profiles and dietary factors among 12 participants who completed the Colorado Trail.
Kiaya Johnston +3 more
wiley +1 more source
Journal of Lipid Research, 2014 LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance.
Brandon Ason +15 more
doaj +1 more source
Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency. [PDF]
, 2013 Non-synonymous mutations affecting both alleles of PCSK1 (proprotein convertase 1/3) are associated with obesity and impaired prohormone processing. We report a proband who was compound heterozygous for a maternally inherited frameshift mutation and a ...
Bochukova, Elena +8 more
core +3 more sources
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies [PDF]
Cardiovascular Research, 2019 AbstractSince the discovery of the role of proprotein convertase subtilisin kexin 9 (PCSK9) in the regulation of low-density lipoprotein cholesterol (LDL-C) in 2003, a paradigm shift in the treatment of hypercholesterolaemia has occurred. The PCSK9 secreted into the circulation is a major downregulator of the low-density lipoprotein receptor (LDLR ...
Seidah, Nabil G. +4 more
openaire +2 more sources
The Journal of Physiology, EarlyView.Abstract figure legend A, Sarcopenic obesity is defined as the age‐related loss of skeletal muscle mass and function that often leads to the progression of comorbidities, such as Alzheimer's disease (AD). Though the exact link between the two diseases is unknown, alterations in brain‐derived neurotrophic factor (BDNF) may be a contributor.
Emily N. Copeland +4 more
wiley +1 more source
Therapeutic Advances in Drug Safety, 2021 Neurocognitive adverse events have been observed with the widespread use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or “statins,” which reduce low-density lipoprotein cholesterol (LDL-C) levels and subsequently cardiovascular risk. The United
Wei C. Yuet, Didi Ebert, Michael Jann
doaj +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition [PDF]
Circulation, 2015 Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the regulation of cholesterol homeostasis. By binding to hepatic low-density lipoprotein (LDL) receptors and promoting their lysosomal degradation, PCSK9 reduces LDL uptake, leading to an increase in LDL cholesterol concentrations.
Nathalie, Bergeron +4 more
openaire +2 more sources